Skip to Main Content

Author Details

David A Quigley
University of California-San Francisco
2008
68
28
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37474400Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.Eur Urol Oncol2024
36821396Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.JCI Insight2023
37584701AARDVARK: an automated reversion detector for variants affecting resistance kinetics.Bioinformatics2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37215032Gene networks reveal stem-cell state convergence during preneoplasia and progression to malignancy in multistage skin carcinogenesis.bioRxiv2023
37330052Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.Ann Oncol2023
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35859180Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.Nature2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
36273492Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.Cancer Res2022
36260524Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2022
36052502Why ARNT Prostate Tumors Responding to Enzalutamide?Cancer Discov2022
33257032One of These Things is Not Like the Others: Targeting ATM-mutant Prostate Cancer.Eur Urol2021
33741908CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.Nat Commun2021
34554200Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.JAMA Oncol2021
34548481Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures.NPJ Genom Med2021
34508103Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3<sup>VNTR</sup> polymorphisms and gene co-expression.NPJ Breast Cancer2021
34326322An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.Nat Commun2021
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
31932493Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.Clin Cancer Res2020
32071145Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.Cancer Discov2020
32624423Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer.Urol Oncol2020
32985524SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression.Sci Rep2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
32139151An integrated molecular profile of endometrioid ovarian cancer.Gynecol Oncol2020
30844389High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.Exp Cell Res2019
31266829DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.Clin Cancer Res2019
31564613Niche-Specific Factors Dynamically Regulate Sebaceous Gland Stem Cells in the Skin.Dev Cell2019
31478838A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS.Elife2019
31010837Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.Clin Cancer Res2019
30918106Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.Mol Cancer Res2019
30928160Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
29431617Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma.Mol Cancer Res2018
30099369DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.J Natl Compr Canc Netw2018
30033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30340047Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
29444438Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.Cell Rep2018
29147603Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue.Oncoimmunology2017
28450426Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors.Cancer Discov2017
26947069Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Cell Rep2016
27506198Panx3 links body mass index and tumorigenesis in a genetically heterogeneous mouse model of carcinogen-induced cancer.Genome Med2016
27425619Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer.Cell Rep2016
25351767Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.Mol Cancer Res2015
26607741Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells.Mol Oncol2015
26223252Equalizer reduces SNP bias in Affymetrix microarrays.BMC Bioinformatics2015
25637275The genetics of splicing in neuroblastoma.Cancer Discov2015
25815003Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14.Front Genet2015
25363767The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.Nature2015
24388359The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors.Mol Oncol2014
  • 1 - 50 of 68

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 10
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 19
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 18
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 34
Matan Hofree
Broad Institute of Harvard and MIT
Career Start Year 2010
Number of shared co-authors 1
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 6
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 6
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 18
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 4
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Christina Curtis
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 13
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 27
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 4
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 8
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 28
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 14
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 9
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 39
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 2
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 21
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 22
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 10
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 15
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 25
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 9
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 51

Collaborators

Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 27
Eric J Small
University of California san francisco
Co-authored papers 18
Rahul Aggarwal
University of California San Francisco
Co-authored papers 15
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 13
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 12
Adam Foye
University of California San Francisco
Co-authored papers 12
Martin E Gleave
University of British Columbia
Co-authored papers 12
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 10
Christopher P Evans
University of California Davis
Co-authored papers 10
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 10
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 10
Martin Sj??str??m
University of California-San Francisco
Co-authored papers 9
Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 9
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 9
Alexander W Wyatt
University of British Columbia
Co-authored papers 8
Jonathan Chou
University of California san francisco
Co-authored papers 8
Paul Lloyd
Bluestar Genomics Inc.
Co-authored papers 7
Christopher A Maher
Washington University in St Louis
Co-authored papers 7
Kim N Chi
University of British Columbia
Co-authored papers 7
Vessela N Kristensen
Faculty of Clinical Medicine, University of Oslo
Co-authored papers 6
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 6
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 6
Owen N Witte
University of California los angeles
Co-authored papers 6
Thomas J George
UF Health Cancer Center
Co-authored papers 5
Anne-Lise B??rresen-Dale
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 5
Joshua M Lang
19University of Wisconsin Carbone Cancer Center.
Co-authored papers 5
Eric Lu
David Geffen School of Medicine at university of california los angeles
Co-authored papers 5
Alana S Weinstein
University of California San Francisco
Co-authored papers 5
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 5
Luke A Gilbert
Arc Institute
Co-authored papers 5
Release 1.2